Tweets
This is an important slide showing how belimumab protected the GFR... ultimately the reason why we are treating #lupus nephritis patients - Prof Michelle Petri
@RheumNow #ACR21 #rheumatology
📌https://t.co/bO3ubqY2bf https://t.co/yuqwlKXDBH
Links:
sheila @RHEUMarampa ( View Tweet )
4 years 9 months ago
#ACR21 Abs#0101 on recombinant #zoster vaccine (RZV) in #IMIDs:
•High proportion of ≥50yos w/ IMIDs received RZV but 15–25% did not get 2nd dose within 6m
•#Vaccination higher in ≥65yos than 50–64yos
•Need better vaccine policy to encourage uptake in pts w/ IMIDs
@RheumNow https://t.co/i5JDJClTyQ
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 9 months ago
@jhrheumatology data on ESRD in Lupus Nephritis, Dr. Michelle Petri. #ACR21 Debate
▶️ 20% risk of renal failure in 20 years is way too high
▶️ C3 strongest predictor, dsDNA also seen
⭐️⬇️ complement, ⬆️dsDNA in lupus nephritis suggests Belimumab is good agent for LN
@Rheumnow https://t.co/ewLAxMgTT0
Eric Dein @ericdeinmd ( View Tweet )
4 years 9 months ago
#ACR21 @RheumNow
Abst#0359 by Garrido-Cumbrera et al. has mapped out the journey from symptom onset to diagnosis of axSpA across 13 European countries.
swethaann23 @swethaann23 ( View Tweet )
4 years 9 months ago
Before the Great Debate:
Next step for Lupus Nephritis?
#ACR21 @Rheumnow
Eric Dein @ericdeinmd ( View Tweet )
4 years 9 months ago
Abstract 0095 Barbhiaya et al examined risk factors for 'Long Haul' COVID-19 in Rheumatology Outpatients in NYC #ACR21 @RheumNow
Akhil Sood MD @AkhilSoodMD ( View Tweet )
4 years 9 months ago
Phase 2 German study demonstrates superiority of TCZ vs PBO in FMF. SAA levels only normalized in TCZ treated patients. Interesting concept that needs to be replicated in larger trials. Abs 0193 #ACR21 #RheumNow @RheumNow https://t.co/awqOpwg3gH https://t.co/lGzYglnkyM
Dr. Rachel Tate @uptoTate ( View Tweet )
4 years 9 months ago
Abst0242 #ACR21 @RheumNow FROST: 1st line Rx of SJIA 73 pts. two study arms: biologics & GC/MTX arm. In biologic arm 14% IL-1i switched to IL-6i, 0% from IL-6i to IL-1i. 50%GC/MTX eventually initiated biologic therapy . 57% of pts d/cGC use, and 75% had cJADAS-10 score ≤ 2.5 https://t.co/vH0AnocTr2
Olga Petryna @DrPetryna ( View Tweet )
4 years 9 months ago
Data science for the dumbs. Very informative talk from Dr Jamie Collins! Surely helpful for me. A good way to decide on the best supervised methods for data analysis in machine learning is to separate according to our goal: to explain or to predict? #ACR2021 @RheumNow https://t.co/J0j6VMkoTV
Aurelie Najm @AurelieRheumo ( View Tweet )
4 years 9 months ago
#ACR21 2nd abstract #0381 from #DESIR cohort by @ElenaNikiUK:
•High disease activity & decreased function assoc w/ greater #WorkDisability
•Not enough to just treat the disease! Need holistic approaches to improve function, QoL & work outcomes.
@RheumNow
https://t.co/jIs3Oj7nbJ
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 9 months ago
Completely new one for me, Dr Taniguchi presenting on using ear ultrasound to diagnose and monitor disease activity in relapsing polychondritis. Appears useful, I suspect in clinical practice more so for diagnosis. Abstr#0169 #ACR21 @RheumNow https://t.co/PLJtkYkP3A
Richard Conway @RichardPAConway ( View Tweet )
4 years 9 months ago
@jhrheumatology Dr. Petri at #ACR21 Great Debate.
Safety issues with Voclosporin:
1) Nephrotoxicity
2) Infection
3) CV Risk Factors
4) Malignancy
5) Neurologic toxicity
6) Osteoporosis
7) Drug interactions
8) Deaths
9) Pregnancy contraindication
@RheumNow https://t.co/wjluivmKNt
Eric Dein @ericdeinmd ( View Tweet )
4 years 9 months ago
